We then conducted gene-based tests of missense and predicted loss-of-function variants in UK Biobank (n = 33,941 CAD cases, 438,394 controls; Supplementary Table 6) and found a strong signal for PCSK9. We did not find evidence for further association with a burden of low-frequency or rare variants (Extended Data Fig. 3 and Supplementary Table 7). This evidence concerns the gene PCSK9 and coronary artery disorder.